Industry PAT Initiatives Mirror FDA’s Cross-Disciplinary Approach
FDA's effort to create a cross-functional, organization-wide approach to advance process analytical technology from a regulatory vantage point is being mirrored by industry as companies seek to convert PAT theory into practice
You may also be interested in...
Collaborating with FDA will be the greatest challenge for industry in implementing the process analytical technology component of FDA's drug quality initiative, AstraZeneca Chemistry, Manufacturing & Controls Group Director Robert Timko said
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials